MetaCap

United Therapeutics Corporation (UTHR)

NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

554.73-4.37 (-0.78%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

UTHR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$23.63B
EPS (TTM)
$26.49
52-week range
455.63 – 614.23
Day range
551.77 – 563.11
Volume / Avg
367.68K / 702.78K
Beta
—

52-week range

$455.63$614.23

UTHR stock today

United Therapeutics (UTHR) closed at $554.73 on Nov 20, down 0.78% (-$4.37), versus the S&P 500's 3.70% decline. Shares are 9.7% below their 52-week high of $614.23, set on Nov 4, 2026 and 21.8% above the 52-week low of $455.63, in the middle of the past year's range. UTHR is up 13.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 16.8%.

At 20.9x trailing earnings, United Therapeutics trades above the peer-group median of 15.0x. Its forward P/E of 17.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About United Therapeutics

Company profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Headquarters
Silver Spring, MD
Employees
1,400
IPO year
1999

Financial highlights

Full financials

In fiscal 2025, United Therapeutics generated $3.18 billion in revenue, up 10.6% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $1.33 billion (+11.7% year over year), for a net margin of 41.9% versus a median of 37.6% in the prior 5 years. Gross margin was 87.9% (down from 89.2%) and operating margin 46.9%.

United Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$3.18B$2.88B$2.33B$1.94B$1.69B
Growth+10.61%+23.63%+20.20%+14.88%+13.63%
Net income$1.33B$1.20B$984.80M$727.30M$475.80M
EPS (diluted)$27.86$24.64$19.81$15.00$10.06

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$687.14+23.87%

  • Strong buy 3
  • Buy 9
  • Hold 2
  • Sell 1
  • Strong sell 0

Target range

Low $390.00High $850.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$5.71 vs $5.85
Surprise
-2.39%

UTHR news

All UTHR news

United Therapeutics peers

Health Care sector
UTHR peer companies
CompanyPrice% ChgMarket capCompare
VTRSViatris Inc.19.63-1.26%$22.50Bvs UTHR
ROIVRoivant Sciences Ltd.38.66-0.78%$28.01Bvs UTHR
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs UTHR
INSMInsmed Incorporated141.33-2.17%$31.01Bvs UTHR
ASNDAscendis Pharma A/S252.73-1.26%$16.58Bvs UTHR
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs UTHR
ZTSZoetis Inc. Class A79.11-2.08%$32.14Bvs UTHR
BBIOBridgeBio Pharma Inc.76.03-2.75%$14.81Bvs UTHR

Indexes, lists and sector

United Therapeutics stock FAQ

What is United Therapeutics's stock price today?

UTHR last traded at $554.73 as of Nov 20, 4:00 PM EST, down 0.78% on the day. Prices are delayed at least 15 minutes.

Does United Therapeutics pay a dividend?

No. United Therapeutics does not currently pay a regular cash dividend.

What is UTHR's P/E ratio?

UTHR trades at a trailing P/E ratio of 20.94 and a forward P/E of 17.44, compared with a median of 15.0 for its closest peers.

Who is United Therapeutics's CEO?

Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. is the chief executive officer of United Therapeutics Corporation, which has about 1,400 employees.

Has UTHR ever split its stock?

Yes. The most recent UTHR stock split was a 2-for-1 split on Sep 23, 2009.

What is the UTHR 52-week high?

The 52-week high for UTHR is $614.23 and the 52-week low is $455.63. The stock is currently 9.7% below its high.

Compare UTHR